Switching delivery formats: A lifecycle management strategy for sterile injectables

Changing delivery formats for sterile injectable therapies can be a valuable strategy for effectively managing the lifecycle of a drug, helping bring it to market faster, make it usable in more situations, provide cost efficiencies for the supplier, and ease medication administration to patients.

Explore the considerations in making the switch, in your free white paper.

Learn more about the factors in transferring delivery formats, including:

Technical considerations
Supply chain requirements
Regulatory requirements
Lead time factors in commercialization
Understanding the physicochemical properties of the molecule
Potential interactions with device components
The impact of formulation and process variables on product stability and quality

Download the Whitepaper

Your company email address

Please select your industry: (max 1)

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
Thermo Fisher Scientific (including its affiliates) may contact me about events, products, services and promotions which Thermo Fisher believes may be of interest to me via email and will process my Personal Information according to its privacy policy. I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com. I acknowledge Thermo Fisher Scientific (including its affiliates) will process my Personal Information according to its Privacy Policy, which includes information about my rights

Please complete all required fields to access the content!

Securing your samples: Strategies for safeguarding critical biological materials

To deliver these therapies to the patients who need them, their success hinges on effective storage and management to maintain integrity throughout their lifecycle. From early development to commercialization, safeguarding sensitive biological materials demands scalable storage solutions and meticulous risk mitigation strategies. Partnering with a CDMO specializing in ultracold storage and biorepository management is critical to preserving product integrity and ensuring continuity throughout every development stage. This webinar will explore how the right CDMO partner can streamline biological material storage, mitigate risks, and provide the scalability needed to support growth from clinical trials to commercial launch, empowering you to advance your pipeline with confidence. Participants will gain insight into:

A New Era of Participant Payment Services

Financial burdens are cited as one of the main barriers to clinical trial recruitment and retention, with traditional methods proving unreliable, complicated and slow. For trial sites and sponsors, the administration burden can be overwhelming, especially on a global scale. Discover how IQVIA’s Participant Payment service is transforming the participant payment landscape, simplifying the process and driving clinical trial success, by offering:

From biomarkers to regulatory compliance, and the impact of AI/ML

The field of precision medicine is rapidly evolving, enabling the development of innovative therapies highly tailored to individuals’ genetic profiles - resulting in revolutionized treatments and improved patient outcomes. Discover expert insights on the current landscape of personalized medicine, including the opportunities and challenges, including: